IONQ Inc vs Smith & Nephew plc — how do they compare? IONQ Inc trades at $35.75 (market cap $12.78B), while Smith & Nephew plc trades at $30.11 (market cap $12.64B). The key difference: IONQ Inc and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.57% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| IONQ | SNN | |
|---|---|---|
Market Cap | $12.78B | $12.64B |
Sector | Technology | Health |
52-Week High | $82.09 | $38.70 |
52-Week Low | $26.59 | $28.73 |
Enterprise Value | $10.78B | $15.41B |
Dividend Yield | — | 2.57% |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.24, down 1.55% with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth projections from $130M in 2025 to $187M in 2026, but remains unprofitable with a net loss of $510M in 2025. Analyst consensus is split with a $73.75 price target representing 115% upside potential. Recent news highlights IonQ's leadership in quantum computing platform development and government validation.
The stock offers significant upside potential based on analyst targets but faces execution risks in achieving profitability. High valuation multiples (P/E 89.18, P/S 58.73) reflect growth expectations, while negative cash flow from operations and competitive threats in quantum computing present substantial risks for investors.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Trailing returns across standard periods
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →